Oral antidiabetic agents in type 2 diabetes

References

• Steppel JH, Horton ES. Beta-cell failure in the pathogenesis of type 2 diabetes mellitus. Curr Diab Rep 2004;4:169–75
   PubMedGoogle Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963–72
   Google Scholar
• Deacon CF, Ahrén B, Holst JJ. Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of type 2 diabetes? Expert Opin Investig Drugs 2004;13: 1091–102
   PubMed Web of Science ®Google Scholar
• Ahrén B. Inhibition of dipeptidyl peptidase-4 (DPP-4) – a novel approach to treat type 2 diabetes. Curr Enzyme Inhibition 2005;1:65–73
   Google Scholar
• Holst JJ, Deacon CF. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 2005;48: 612–15
   PubMed Web of Science ®Google Scholar
• Ahrén B. Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties. Drugs 2006 15:431–42
   Web of Science ®Google Scholar
• Bell DSH. Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy. Clin Ther 2004;26:1714–27
   PubMed Web of Science ®Google Scholar
• Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 2004;64:1339–58
   PubMed Web of Science ®Google Scholar
• Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002;287:360–72
   PubMed Web of Science ®Google Scholar
• Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005;65:385–411
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352: 837–53
   Google Scholar
• Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383–93
   PubMed Web of Science ®Google Scholar
• Kahn SE, Haffner SM, Heiser MA, et al., for the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427–43
   Google Scholar
• Lebovitz HE. Oral therapies for diabetic hyperglycemia. Endocrin Metab Clin North Am 2001;30:909–33
   PubMed Web of Science ®Google Scholar
• Zimmerman BR. Sulfonylureas. Endocrinol Metab Clin North Am 1997;26:511–21
   PubMed Web of Science ®Google Scholar
• Klimt CR, Knatterud GL, Meinert CL, Prout TE. The University Group Diabetes Program: a study of the effect of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. I. Design, methods, and baseline characteristics. II. Mortality results. Diabetes 1970; 19(Suppl 2):747–830
   Google Scholar
• Fuhlendorff J, Rorsman P, Kofod H, et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 1998;47:345–51
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Hassman DR, Madder RD, et al., for the Repaglinide Versus Nateglinide Comparison Study Group. Diabetes Care 2004;27:1265–70
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352: 854–65
   Google Scholar
• Diabetes Prevention Program Research Group. Reduction of the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403
   PubMed Web of Science ®Google Scholar
• Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281:2005–12
   PubMed Web of Science ®Google Scholar
• Misbin RL. The phantom of lactic acidosis due to metformin in patients with diabetes. Diabetes Care 2004;27:1791–3
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106–18
   Google Scholar
• Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure. Diabetes Care 2004;27:256–63
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular event in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 2005;366:1279–89
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H. The PROactive study: some answers, many questions. Lancet 2005;366:1241–2
   PubMed Web of Science ®Google Scholar
• Chiasson JL, Josse RG, Gomis R, et al. Acarbose for the prevention of diabetes mellitus the STOP-NIDDM randomized trial. STOP-NIDDM Research Group. JAMA 2003;290: 486–94
   PubMed Web of Science ®Google Scholar
• Drucker D. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003;26:2929–40
   PubMed Web of Science ®Google Scholar
• Ahrén B, Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res 2004;36: 867–76
   Google Scholar
• Ahrén B, Landin-Olsson M, Jansson P-A, et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004;89:2078–84
   PubMed Web of Science ®Google Scholar
• Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004;287:E199–206
   PubMed Web of Science ®Google Scholar
• Drucker DJ. Glucagon-like peptide-1 and the islet beta-cell: augmentation of beta-cell proliferation and inhibition of apoptosis. Endocrinology 2003;144:5145–8
   PubMed Web of Science ®Google Scholar
• Pospisilik JA, Martin J, Doty T, et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozocin-induced diabetic rats. Diabetes 2003;52:741–50
   PubMed Web of Science ®Google Scholar
• Duttaroy A, Voelker F, Merriam K, et al. The DPP-4 inhibitor vildagliptin increases pancreatic beta-cell neogenesis and decreases apoptosis [abstract]. Presented at: American Diabetes Association – 65th Scientific Sessions; June 10–14, 2005; San Diego, Calif. Abstract 572–P
   Google Scholar
• Ahrén B, Gomis R, Standl E, et al. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF 237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004;27: 2874–80
   Google Scholar
• Deacon CF. MK-431 (Merck). Curr Opin Investig Drugs 2005;6:419–26
   PubMedGoogle Scholar
• Mari A, Sallas M, He YL, et al. Vildagliptin, a dipetidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005;90:4888–94
   PubMed Web of Science ®Google Scholar
• Herman GA, Bergman A, Liu F, et al. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol 2006;46:876–86
   PubMed Web of Science ®Google Scholar
• Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 2006;60:1454–70
   PubMed Web of Science ®Google Scholar
• Kendall DM, Kim D, Maggs D. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of emerging therapies for type 2 diabetes. Diabetes Technol Ther 2006;8: 385–96
   Google Scholar
• Miller SA, Onge EL. Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Ann Pharmacother 2006;40:1336–43
   PubMed Web of Science ®Google Scholar
• Ahrén B, Pacini G, Foley J, et al. Improved meal-related β-cell function and insulin sensitivity by the dipetidyl peptidase IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005;28: 1936–40
   Google Scholar
• Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632–7
   PubMed Web of Science ®Google Scholar
• Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638–43
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–19
   PubMed Web of Science ®Google Scholar
• Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006;49:2564–71
   PubMed Web of Science ®Google Scholar
• Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Hormone Metab Res 2007, in press
   Google Scholar
• Rosenstock J, Baron M, Dejager S, et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 2007;30:217–23
   PubMed Web of Science ®Google Scholar
• Dejager S, Lebeaut A, Couturier A, et al. Sustained reduction in HBA1c during one-year treatment with vildaglitin in patients with type 2 diabetes (T2DM) [abstract]. Diabetes 2006;55\(Suppl 1):A29. Abstract 120–OR
   Google Scholar
• Nathwani A. The use of vildagliptin for treatment of patients with type 2 diabetes mellitus [abstract]. Presented at: American Diabetes Association – 66th Scientific Sessions, June 9–13, 2006; Washington, DC
   Google Scholar
• Rosenstock J, Brazg R, Andryuk PJ, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006;28:1556–68
   PubMed Web of Science ®Google Scholar
• Stein P. Sitagliptin: a novel dipeptidyl peptidase-4 inhibitor for the treatment of patients with type 2 diabetes [abstract]. Presented at: American Diabetes Association – 66th Scientific Sessions; June 9–13, 2006; Washington, DC
   Google Scholar
• Bosi E, Camisasca RP, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007, published online 2 February 2007, doi:10.2337/dc06–1732
   Google Scholar
• Rosenstock J, Baron MA, Camisasca R-P, et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007;9: 175–85
   Google Scholar
• Fonseca V, Dejager S, Albrecht D, et al. Vildagliptin as add-on to insulin in patients with type 2 diabetes (T2DM) [abstract]. Diabetes 2006;55\(Suppl 1):A111. Abstract 467–P
   Google Scholar
• Matikainen N, Manttari S, Schweizer A, et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006;49:2049–57
   PubMed Web of Science ®Google Scholar
• Nathwani A, Lebeaut A, Byiers S, et al. Reduction in blood pressure in patients treated with vildagliptin as monotherapy or in combination with metformin for type 2 diabetes [abstract]. Diabetes 2006;55\(Suppl 1):A113. Abstract 474–P
   Google Scholar
• He YL, Sabo R, Wang Y, et al. The influence of hepatic impairment on the pharmacokinetics of vildagliptin [abstract]. Diabetes 2006;55\(Suppl 1):A469. Abstract 2024–PO
   Google Scholar
• He YL, Sabo R, Wang Y. Influence of age, gender and BMI on the pharmacokinetics and pharmacodynamics of vildagliptin [abstract]. Clin Pharm Ther 2006;79:P63. Abstract PIII–19
   Google Scholar
• Januvia [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2006
   Google Scholar
• Riddle MC, Drucker DJ. Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Diabetes Care 2006;29:435–49
   PubMed Web of Science ®Google Scholar
• Buse JB, Henry RR, Han J, et al., for the Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628–35
   Google Scholar
• DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092–100
   PubMed Web of Science ®Google Scholar
• Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083–91
   PubMed Web of Science ®Google Scholar
• Ratner RE, Maggs D, Nielsen LL, et al. Long term effects of exenatide therapy over 82 weeks in over-weight metformin-treated patients with type 2 diabetes mellitus. Diab Obes Metab 2006;419–28
   PubMed Web of Science ®Google Scholar
• Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005;143: 559–69
   PubMed Web of Science ®Google Scholar
• Byetta [package insert]. San Diego, Calif: Amylin Pharmaceuticals Inc.; 2006
   Google Scholar
• Vilsboll T, Zdravkovic M, Le-Thi T, et al. Liraglutide significantly improves glycemic control, and lowers body weight without risk of either major or minor hypoglycemic episodes in subject with type 2 diabetes [abstract]. Diabetes 2006;55\(Suppl 1):A462. Abstract A27–28, Abstract 115–OR
   Google Scholar
• Vilsboll T, Zdravkovic M, Le-Thi T, et al. Liraglutide treatment, blood pressure and biomarkers of cardiovascular risk in patients with type 2 diabetes: 14 weeks monotherapy study [abstract]. Diabetes 2006;55\(Suppl 1):A465. Abstract 2007–PO
   Google Scholar